Table 1.
Clinicopathological Data | n | Percentage (%) |
---|---|---|
Age (years) | ||
≤50 | 18 | 69.2 |
>50 | 8 | 30.8 |
Primary tumor size (cm) | ||
≤5 | 16 | 61.5 |
>5 | 10 | 38.5 |
Lymph node metastasis | ||
Present | 21 | 80.8 |
Absent | 5 | 19.2 |
TNM stage | ||
I–II | 11 | 42.3 |
III–IV | 15 | 57.7 |
Histopathological grade | ||
I–II | 15 | 57.7 |
III | 11 | 42.3 |
ER status | ||
Positive | 13 | 50.0 |
Negative | 13 | 50.0 |
PR status | ||
Positive | 11 | 42.3 |
Negative | 15 | 57.7 |
HER-2 status | ||
Positive | 12 | 46.2 |
Negative | 14 | 53.8 |
Molecular subtype | ||
Luminal A | 5 | 19.2 |
Luminal B | 9 | 34.6 |
Her-2 overexpressing | 8 | 30.8 |
Triple negative | 4 | 15.4 |
TNM, tumor, node, metastasis; ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal growth factor receptor-2.